NCT00578448

Belatacept Pharmacokinetic Trial in Renal Transplantation

An Open-label Pharmacokinetic Study in De Novo Renal Transplant Subjects Receiving a Belatacept Based Immunosuppressant Regimen

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the pharmacokinetics and safety of belatacept in de novo renal transplant subjects treated with belatacept-based immunosuppressant medication

Conditions

• Renal Transplantation

Interventions

Type	Name	Description
DRUG	Belatacept	IV infusion

Timeline

• Start date: 2008-03-01
• Primary completion: 2009-03-01
• Completion: 2012-09-01
• First posted: 2007-12-21
• Last updated: 2014-01-17
• Results posted: 2013-12-17

Locations

5 sites across 3 countries: United States, Argentina, Mexico